Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.52 |
| ▸ | SHBG | P04278 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13885099 | 0.83 | SHBG (0.47) | ESR1ESR2SHBGHSD17B1HSD17B2 | |
| SCHEMBL4471795 | 0.79 | SHBG (0.55) | ESR1ESR2SHBGHSD17B1HSD17B2 | |
| SCHEMBL30343458 | 0.79 | SHBG (0.55) | ESR1ESR2SHBGHSD17B1HSD17B2 | |
| SCHEMBL1597362 | 0.79 | SHBG (0.55) | ESR1ESR2SHBGHSD17B1HSD17B2 | |
| SCHEMBL27272818 | 0.78 | SHBG (0.40) | SHBGNR3C1PGRARLMNA | |
| SCHEMBL8816389 | 0.77 | SHBG (0.53) | ESR1ESR2SHBGHSD17B1HSD17B2 | |
| SCHEMBL1596219 | 0.77 | SHBG (0.53) | ESR1ESR2SHBGHSD17B1HSD17B2 | |
| SCHEMBL22326111 | 0.77 | ALDH1A1 (0.46) | ESR1ESR2SHBG | |
| SCHEMBL22326126 | 0.77 | ESR1 (0.50) | ESR1ESR2HSD17B1HSD17B2LMNA | |
| SCHEMBL11050693 | 0.77 | ESR1 (0.50) | ESR1ESR2NR3C1PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020162408-A1 | METHOD FOR PRODUCING 1,1,1-TRIFLUORO-2,2-BISARYLETHANE, AND 1,1,1-TRIFLUORO-2,2-BISARYLETHANE | セントラル硝子株式会社 | 2020-08-13 | — | — | WO | claimed |
| US-12435185-B2 | Method for producing 1,1,1-trifluoro-2,2-bisarylethane, and 1,1,1-trifluoro-2,2-bisarylethane | CENTRAL GLASS COMPANY, LIMITED (JP) | 2025-10-07 | — | — | US | disclosed |
| US-12098238-B2 | Curable resin, curable resin composition, cured product, electronic device, laminated board material, electronic component encapsulant, and method for producing curable resin | CENTRAL GLASS COMPANY, LIMITED (JP) | 2024-09-24 | — | — | US | disclosed |
| EP-4089131-B1 | CURABLE RESIN, CURABLE RESIN COMPOSITION, CURED PRODUCT, ELECTRONIC DEVICE, LAMINATED BOARD MATERIAL, ELECTRONIC COMPONENT ENCAPSULANT, AND METHOD FOR PRODUCING CURABLE RESIN | CENTRAL GLASS CO LTD (JP) | 2024-06-26 | — | — | EP | disclosed |
| US-20230097638-A1 | Curable Resin, Curable Resin Composition, Cured Product, Electronic Device, Laminated Board Material, Electronic Component Encapsulant, and Method for Producing Curable Resin | CENTRAL GLASS COMPANY, LIMITED (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4089131-A1 | CURABLE RESIN, CURABLE RESIN COMPOSITION, CURED PRODUCT, ELECTRONIC DEVICE, LAMINATED BOARD MATERIAL, ELECTRONIC COMPONENT ENCAPSULANT, AND METHOD FOR PRODUCING CURABLE RESIN | Central Glass Company, Limited (JP) | 2022-11-16 | — | — | EP | disclosed |
| US-20220106444-A1 | Method for Producing 1,1,1-Trifluoro-2,2-Bisarylethane, and 1,1,1-Trifluoro-2,2-Bisarylethane | CENTRAL GLASS COMPANY, LIMITED (JP) | 2022-04-07 | — | — | US | disclosed |
| WO-2020162408-A1 | METHOD FOR PRODUCING 1,1,1-TRIFLUORO-2,2-BISARYLETHANE, AND 1,1,1-TRIFLUORO-2,2-BISARYLETHANE | セントラル硝子株式会社 | 2020-08-13 | — | — | WO | disclosed |
| WO-2020162408-A1 | METHOD FOR PRODUCING 1,1,1-TRIFLUORO-2,2-BISARYLETHANE, AND 1,1,1-TRIFLUORO-2,2-BISARYLETHANE | セントラル硝子株式会社 | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106444-A1 | Method for Producing 1,1,1-Trifluoro-2,2-Bisarylethane, and 1,1,1-Trifluoro-2,2-Bisarylethane | NAF1, FXR1, AFF1 | ESR1 4737/4885ESR2 3744/4885SHBG 3564/4885 |
| US-12435185-B2 | Method for producing 1,1,1-trifluoro-2,2-bisarylethane, and 1,1,1-trifluoro-2,2-bisarylethane | NAF1, FXR1, AFF1 | ESR1 4737/4885ESR2 3744/4885SHBG 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.